India is emerging as a global hub for medical tourism, attracting patients from the US, UK, and beyond with lower costs and advanced treatments. However, structural challenges, regulatory gaps, and patient protection issues threaten to impede sustainable growth as the sector prepares for a significant expansion by 2030.
India’s rise as a medical tourism destination is no longer a niche story. Patients from the US, UK, Canada and Gulf states are increasingly travelling to Indian hospitals for major procedures, drawn by prices that can be a fraction of those in the West and by shorter waiting times than those common under systems such as the NHS. The appeal is especially strong for complex treatment, from cardiac surgery and orthopaedics to cancer care and organ transplants, with India positioning itself as a lower-cost alternative without, it says, sacrificing expertise.
The market’s growth outlook is substantial. Industry estimates cited in the source material suggest India’s medical tourism sector could move from about $8.7bn in 2025 to more than $16bn by 2030. That expansion is being supported by government-backed branding such as Heal in India and by medical visas, while more than 40 hospitals are said to hold Joint Commission International accreditation and more than 600 to be NABH certified. Super-speciality centres are also deploying robotic surgery, proton beam therapy and AI-based diagnostics, adding to India’s appeal for international patients seeking advanced care.
Yet the same reports make clear that the sector’s promise is being held back by basic structural problems. Most foreign patients still go to a small group of metro cities, especially Delhi-NCR, Mumbai, Chennai, Bengaluru, Hyderabad and Kolkata, leaving many tier-two and tier-three cities underused despite having capable hospitals. That concentration places strain on beds and staff in the biggest urban centres, while limited direct international flights and weaker transport links make it harder to spread demand more evenly across the country. According to research from ORF and other industry analyses, the lack of a coherent regulatory framework also raises questions about how sustainably the sector can grow.
Pricing and patient protection are another weak point. The summaries describe a marketplace in which unregulated intermediaries can charge arbitrary fees for treatment, accommodation and visa help, while foreign patients may be quoted different prices for the same procedure at different hospitals. Language and cultural gaps add further risk, particularly for patients arriving from Russia, Central Asia, the Gulf and parts of Africa where Arabic, Russian or French may be the main language. The absence of enough translators and patient coordinators can make consent forms, treatment plans and medication instructions harder to understand, increasing the chance of mistakes.
Follow-up care remains a final hurdle. Once patients return home, telemedicine can keep doctors in touch, but complications can become difficult to manage because of cross-border legal and insurance barriers. The reports also point to broader friction around visa extensions, FRRO formalities, cleanliness outside premium hospitals and the wider travel experience, all of which can shape a patient’s impression of India. Analysts argue that if the country wants to turn medical tourism into a durable global advantage, it will need mandatory registration of facilitators, clearer pricing, better language support, stronger logistics and more consistent regulation across states.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
